Search Results 1441-1450 of 17803 for monoclonal antibody

  1. A Multi-center, Open-label Extension, Safety Study Of Mepolizumab In Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

    Subjects with any history of hypersensitivity to any monoclonal antibody (including mepolizumab). Subjects with current malignancy or malignancy that ...

  2. Medical Research & Education - Mayo Clinic News Network

    Is the definition of Alzheimer's disease changing? Dana Sparks. November 6, 2018. Mayo researchers correlate specific antibody with relapse of neurological ...

  3. Medical Research & Education - Mayo Clinic News Network

    Mayo Clinic expert answers questions about antibody testing for COVID-19 ... Science Saturday: Antibody testing, in pictures featured image. Research.

  4. Clinical trials - Oncology (Medical)

    This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

  5. A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer - Mayo Clinic

    History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies; Exposure to another investigational drug within 42 days of ...

  6. Clinical trials - Oncology (Medical)

    A Study of Hematopoiesis in Patients with Monoclonal ... Monoclonal B Cell Lymphocytosis (MBL) and B ... antibodies) treatment, CPI-naïve hepatocellular ...

  7. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

    Monoclonal antibody (ies). At least 28 days since the last dose of monoclonal antibody prior to first dose of tazemetostat. Immunotherapy (e.g., tumor vaccine).

  8. A Study of the Safety and Effectiveness of Combined Copaxone and Estriol for Relapsing Remitting Multiple Sclerosis - Mayo Clinic

    Monoclonal antibody; T cell vaccination; Cladribine; Bone marrow transplantation; Azathioprine; Cyclophosphamide; Methotrexate; Mitoxantrone; Cyclosporin ...

  9. Department of Immunology - Mayo Clinic Research

    Chronic inflammation; Infections; Tissue, organ and bone marrow transplantation. Departmental faculty also have oversight responsibilities for the Antibody ...

  10. Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) - Mayo Clinic

    Allergies, hypersensitivity, or intolerance to daratumumab, hyaluronidase, monoclonal antibodies (mAbs), human proteins, or their excipients, or known ...